What are the side effects of filgotinib?

Filgotinib (Filgotinib) is a selective Janus kinase 1 (JAK1) inhibitor, mainly used to treat autoimmune diseases such as rheumatoid arthritis. Although it has excellent therapeutic effects, there are also certain adverse reactions and precautions in clinical application.

In clinical studies, the most common adverse reactions of filgotinib include nausea, upper respiratory tract infection, urinary tract infection, dizziness, and lymphopenia. The occurrence of nausea may be related to the effects of drugs on gastrointestinal function, while upper respiratory tract infections and urinary tract infections suggest that patients may be at higher risk of infection when receiving such drugs. The occurrence of these infections may in some cases result in the need to discontinue the drug or modify the regimen. Dizziness may affect the patient's daily life, so drive and operate machinery with caution during medication.

In addition, the use of filgotinib comes with some more serious warnings and precautions. Infection and viral reactivation are special concerns when using this drug, especially in patients with a history of underlying infection. In addition, studies have shown that this class of drugs may be associated with an increased risk of malignancy, so patients' health needs to be monitored regularly during use. Cardiovascular risks cannot be ignored, especially patients with underlying cardiovascular diseases, who need to be particularly careful when using filgotinib.

Venous thromboembolism is another important adverse reaction. If patients feel leg swelling, pain or difficulty breathing during medication, they should seek medical attention immediately to rule out the possibility of venous thromboembolism. In addition, filgotinib may be toxic to the fetus, so women who are pregnant or planning pregnancy must be very cautious when using this drug, and it is recommended to use it under the guidance of a doctor.

Reference materials:https://www.medicines.org.uk/emc/product/11809/smpc#gref